Souhaitez-vous accéder aux communiqués récents ?

Navamedic ASA invites you to follow an online presentation of the second quarter 2017 figures. The presentation will be webcasted at www.navamedic.com - investor relations - presentations -...

Navamedic ASA has today, 6 June 2017, held an annual general meeting. All resolutions were made in accordance with the board's/nomination committee's proposals. The minutes from the general meeting is...

Oslo, May 31, 2017 - Navamedic ASA (OSE: NAVA) announced today that it has been granted a patent by the European Patent Office for the base technology of Sippi®, using capacitance as a volume...

Mattias von Haartman, salgsdirektør i Navamedic ASA solgte den 19.05.17 , 20 000 aksjer til en kurs på NOK 11,50. Beholdningen utgjorde 0,18 % av den totale utestående aksjeposten i Navamedic. Von...

The Annual General Meeting in Navamedic ASA will take place on Tuesday 6 June 2017 at 13.00 at Hotel Continental, Stortingsgaten 24-26, Oslo. Please find attached the annual report. Notice of the...

Oslo, 10 May 2017 - Navamedic ASA (OSE: NAVA), reported revenues of NOK 78.2 million in the first quarter of 2017 (NOK 60.8 million in Q1 2016), representing a growth of 28.6%, in part due to a...

Oslo, 10. mai 2017 - Navamedic ASA (OSE: NAVA) rapporterte driftsinntekter på NOK 78,2 millioner i første kvartal 2017 (NOK 60,8 millioner i første kvartal 2016), med en økning på 28,6%, delvis...

Navamedic ASA invites you to a presentation of the first quarter 2017 figures. The presentation takes place at Hotel Continental, Stortingsgaten 24/26, 0117 Oslo, Wednesday 10 May. The presentation...

Oslo, May 2, 2017 - Navamedic ASA (OSE: NAVA), the Norwegian medtech and pharmaceutical products company, today announced it has entered into a five-year agreement with Orexigen Therapeutics Ireland,...

Attached: The Annual Report 2016 for Navamedic ASA. The report will also be avaiable on Navamedic's website: www.navamedic.com For further information please contact:  CFO Toril...